Areas where scientific evidence is lacking or incomplete.
Current trials span 36-80 weeks. There is no data regarding effects over 5-year or 10-year periods, particularly concerning chronic glucagon activation on heart and metabolic systems.
Implications: Patients considering chronic use have no long-term safety benchmark. The glucagon component — novel in this drug class — has no precedent for multi-year activation.
No randomized head-to-head trials against semaglutide (Wegovy) or tirzepatide (Zepbound). All current comparisons are cross-trial, which is imperfect due to different patient populations and study designs.
Implications: Clinicians and patients cannot make fully informed choices between incretin therapies without direct comparative data.
Limited data on durability of weight loss after discontinuation. Early signals suggest weight regain is highly probable without long-term use, but exact maintenance protocols and success rates remain unclear.
Implications: The framing of obesity as a 'chronic condition' implies lifelong therapy — but no data confirms whether dose reduction or periodic use could maintain benefits.
Large gaps for: pregnancy/breastfeeding (no fetal development data), Type 1 diabetes (contraindicated/unexplored), pediatric use (no data), and elderly populations (75+, excluded from trials).
Implications: Significant portions of the population who might benefit have no evidence base for safety or efficacy.
The exact contribution of brown adipose tissue (BAT) to Retatrutide's energy expenditure increase in humans remains a subject of academic debate. Whether combining cold exposure with Retatrutide enhances the metabolic effect is unverified in clinical settings.
Implications: The 'metabolic fire' narrative is plausible but not fully confirmed at the mechanistic level in humans.
The 'black box' warning for medullary thyroid carcinoma is based on animal studies only. Human risk is described as 'unknown' and will require long-term post-marketing surveillance.
Implications: A critical safety question that cannot be answered until years of post-approval real-world data are collected.
No official pricing, manufacturing supply chain details, or confirmed FDA/MHRA submission dates from Eli Lilly as of early 2026.
Implications: Patients and clinicians cannot plan for real-world adoption without cost, availability, and timeline data.
Expert disagreements and competing evidence.
Dysesthesia affects 20.9% of participants at the 12 mg dose
TRIUMPH-4 trial (obesity and osteoarthritis population)
Source: TRIUMPH-4 Phase 3 trial data
Dysesthesia affects only 4.4% at the same 12 mg dose
TRANSCEND-T2D-1 trial (type 2 diabetes population)
Source: TRANSCEND-T2D-1 trial data
Resolution
The significant discrepancy (20.9% vs 4.4%) likely reflects differences in trial populations rather than true variability. Obesity/osteoarthritis patients may have heightened neurological sensitivity. Both figures are from Phase 3 data.
Peak heart rate increase of up to 6.7 beats per minute
Specific clinical measurement data
Source: Individual trial endpoint analysis
Heart rate increase is typically between 5 and 10 beats per minute
Aggregate clinical guidance
Source: Clinical protocol guidelines
Resolution
Not a true contradiction — the 6.7 bpm figure appears to be a specific trial measurement, while the 5-10 bpm range represents the general clinical guidance. Both are within the same order of magnitude.
"No weight loss plateau was observed" through 40 weeks
Manufacturer topline results from TRANSCEND-T2D-1
Source: Eli Lilly TRANSCEND-T2D-1 press release
Weight loss plateaus are normal around week 40-48 and clinicians should "manage expectations"
Clinical fatigue management guide
Source: Clinical practice guidelines
Resolution
Direct contradiction. The manufacturer's claim of 'no plateau' through 40 weeks conflicts with clinical guidance suggesting plateaus at 40-48 weeks. The manufacturer's statement may reflect trial-average curves that mask individual variation.
Standard Phase 3 TRIUMPH titration starts at 2 mg once weekly
Multiple Phase 3 TRIUMPH trial protocols
Source: TRIUMPH trial design documentation
Starting dosage for weeks 1-4 is 1 mg once weekly
Retatrutide dosage schedule table
Source: Conservative dosing protocol reference
Resolution
Both are valid protocols. The 2 mg start reflects the Phase 3 clinical trial standard, while the 1 mg start represents a conservative approach for high-sensitivity patients. The Synthesis resource uses 1 mg as the 'safe-default' and 2 mg as the 'advanced' starting dose.
86% reduction in liver fat at the 12 mg dose
Mean relative reduction in liver fat (MRI-PDFF)
Source: Phase 2a MASLD sub-study
93% of participants achieved normal liver fat levels (<5%)
Percentage of patients reaching normal threshold
Source: Phase 2a MASLD sub-study
Resolution
Not a contradiction — these are two different metrics measuring the same phenomenon. The 86% figure is the mean relative fat reduction; the 93% figure is the percentage of patients who crossed below the clinical threshold. Both are accurate but measure different things.